1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for India Diabetes Drug Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in India Diabetes Drug Market
4. India Diabetes Drug Market by Drug
Type
4.1. Injectable Drugs
4.1.1. Insulin
4.1.2. Leraglutide
4.1.3. Aspart
4.1.4. Glargine
4.1.5. Exenatide
4.1.6. Pramlintide
4.2. Oral Drugs
4.2.1. Biguanides
4.2.2. Sulfonylureas
4.2.3. Meglitinides and D-phenylalanine
Derivatives
4.2.4. Thiazolidinediones
4.2.5. DPP-4 Inhibitors
4.2.6. Alpha-glucosidase
Inhibitors
5. India Diabetes Drug Market by
Application
5.1. Type 1 Diabetes
5.2. Type 2 Diabetes
6. Company Profiles
6.1. Company 1
6.2. Company 2
6.3. Company 3
6.4. Company 4
6.5. Company 5
1. Report Overview
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches
2. Executive Summary
3. Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.4. Challenges
3.3. PEST-Analysis
3.4. Porter's Diamond Model for India Diabetes Drug Market
3.5. IGR-Growth Matrix Analysis
3.6. Competitive Landscape in India Diabetes Drug Market
4. India Diabetes Drug Market by Drug
Type
4.1. Injectable Drugs
4.1.1. Insulin
4.1.2. Leraglutide
4.1.3. Aspart
4.1.4. Glargine
4.1.5. Exenatide
4.1.6. Pramlintide
4.2. Oral Drugs
4.2.1. Biguanides
4.2.2. Sulfonylureas
4.2.3. Meglitinides and D-phenylalanine
Derivatives
4.2.4. Thiazolidinediones
4.2.5. DPP-4 Inhibitors
4.2.6. Alpha-glucosidase
Inhibitors
5. India Diabetes Drug Market by
Application
5.1. Type 1 Diabetes
5.2. Type 2 Diabetes
6. Company Profiles
6.1. Company 1
6.2. Company 2
6.3. Company 3
6.4. Company 4
6.5. Company 5